We are Eyenovia Inc., and we are making it possible.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies for the treatment of progressive myopia, presbyopia and improving diagnostic eye exams. Our breakthrough technology enables these first-in-class microdosed drugs that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.